{
  "id": "common-variable-immunodeficiency",
  "title": "Common Variable Immunodeficiency",
  "lang": "en",
  "source_lang": "en",
  "summary": "Common variable immunodeficiency is a heterogeneous immune disorder characterized by low antibody levels, impaired antibody responses, recurrent infections, and sometimes autoimmune or inflammatory complications.",
  "category": "health",
  "subcategory": "diseases",
  "type": "concept",
  "aliases": [
    "CVID",
    "Common variable immune deficiency"
  ],
  "generated_at": "2026-11-03",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/common-variable-immunodeficiency/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/common-variable-immunodeficiency/",
      "json": "https://aiwiki.page/zh/common-variable-immunodeficiency.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Common variable immunodeficiency (CVID) is a heterogeneous group of disorders in which the immune system produces insufficient amounts of functional antibodies. It is characterized by persistently reduced blood concentrations of immunoglobulin G (IgG), usually accompanied by reduced immunoglobulin A (IgA), immunoglobulin M (IgM), or both, and impaired antibody responses. CVID is classified as a primary immunodeficiency, also termed an inborn error of immunity. Its manifestations range from recurrent respiratory infections to autoimmune disease, chronic inflammation, and abnormal lymphoid tissue growth. The name describes variability between affected individuals, not a disorder that necessarily fluctuates between normal and abnormal immunity."
    },
    {
      "heading": "Epidemiology and presentation",
      "text": "CVID is among the more frequently recognized symptomatic primary antibody deficiencies. Estimates of its prevalence vary across populations and diagnostic systems, commonly falling between approximately 1 in 25,000 and 1 in 50,000 people. Limited recognition and access to immunological testing affect these estimates.\n\nSymptoms can begin in childhood or adulthood, and diagnosis may follow years of recurrent illness. Both sexes are affected. Although a minority of cases occur in families with other antibody deficiencies, most affected individuals have no clearly established family history.\n\nCVID is generally not diagnosed before about four years of age because immune maturation and transient childhood antibody deficiencies can complicate interpretation. Earlier or unusually severe presentations may instead indicate a more specifically defined immune disorder."
    },
    {
      "heading": "Biological basis",
      "text": "Antibodies are proteins that recognize pathogens and other foreign substances. They support infection control through mechanisms including neutralization and the marking of microbes for destruction.\n\nIn many people with CVID, B cells are present in the blood but do not mature normally into antibody-secreting plasma cells or develop an adequate population of class-switched memory B cells. These memory cells normally contribute to sustained, specialized antibody responses after infection or immunization.\n\nThe defect is not always restricted to B cells. Abnormalities in T cells, immune signaling, and immune regulation occur in some patients. These findings help explain why CVID can involve both inadequate protection against infection and inappropriate immune activity against the body’s own tissues.\n\nGenetic heterogeneity\n\nCVID does not have a single genetic cause. In most people meeting clinical criteria, no single causative genetic alteration is identified. Some have disease-causing variants in genes involved in B-cell function, communication between immune cells, or immune regulation.\n\nModern genetic testing can reclassify some CVID-like presentations as specific monogenic disorders. This distinction can be important because particular disorders have different associated complications and, in some cases, different treatment options. Conversely, finding a genetic variant does not by itself establish that the variant caused the antibody deficiency."
    },
    {
      "heading": "Clinical manifestations",
      "text": "Recurrent infections\n\nThe most characteristic infections involve the sinuses, middle ears, bronchi, and lungs. Repeated episodes of otitis media and pneumonia may occur, often involving encapsulated bacteria such as Streptococcus pneumoniae and Haemophilus influenzae.\n\nRepeated or persistent lower respiratory infections can lead to bronchiectasis, an irreversible widening of the airways associated with impaired mucus clearance and further infections.\n\nGastrointestinal infections also occur. Giardia duodenalis is a recognized cause of persistent diarrhea in people with antibody deficiency. Other infections may be prolonged or recurrent. Severe opportunistic infections are less typical of uncomplicated antibody deficiency and can indicate additional defects in cellular immunity or another immune disorder.\n\nAutoimmune and inflammatory complications\n\nSome individuals first present with autoimmune disease rather than recurrent infection. Autoimmune destruction of platelets or red blood cells is a characteristic manifestation; the latter can cause autoimmune hemolytic anemia.\n\nChronic inflammatory complications can affect the lungs, gastrointestinal tract, liver, and other organs. CVID-associated enteropathy may cause diarrhea, weight loss, and impaired nutrient absorption. Its intestinal changes can resemble celiac disease, but the underlying process and response to dietary exclusion are not necessarily the same.\n\nSome patients develop granulomas: organized collections of immune cells within tissues. A recognized pulmonary complication is granulomatous–lymphocytic interstitial lung disease, which involves inflammatory and lymphoid changes in the lungs. It is distinct from infection-related airway damage, although both can coexist.\n\nLymphoid enlargement and malignancy\n\nEnlargement of lymph nodes and the spleen can occur because of nonmalignant immune-cell proliferation. These findings do not necessarily indicate cancer.\n\nNevertheless, CVID is associated with an increased risk of certain malignancies, particularly lymphoma and stomach cancer. Reported risk estimates differ between patient cohorts. Persistent infection, chronic inflammation, and impaired immune regulation may contribute."
    },
    {
      "heading": "Diagnosis",
      "text": "CVID is a diagnosis based on clinical and laboratory findings together with the exclusion of alternative explanations. No single test establishes it in every case.\n\nCommon elements of diagnostic assessment include:\n\n- Persistently low immunoglobulin concentrations: IgG is substantially below the age-adjusted reference range, usually with low IgA and sometimes low IgM. Measurements are generally repeated.\n- Impaired antibody function: testing may show inadequate production of specific antibodies following selected vaccines.\n- Immune-cell characterization: blood testing can measure B-cell and T-cell populations, including class-switched memory B cells.\n- Exclusion of secondary causes: low antibody concentrations can result from certain medicines, blood cancers, or loss of proteins through the kidneys or gastrointestinal tract.\n- Assessment for alternative primary immune disorders: profound T-cell deficiency or a characteristic genetic finding may support a different diagnosis.\n\nDiagnostic frameworks differ in details. Some require clinical manifestations and reduced IgA as well as IgG; some allow particular B-cell abnormalities as an alternative to demonstrating poor vaccine responses. Antibody deficiency alone therefore does not automatically establish CVID.\n\nThe differential diagnosis includes other primary antibody deficiencies and secondary immunodeficiency. Distinguishing persistent CVID from transient antibody deficiency is especially important in children.\n\nAntibody-based tests for infections and autoimmune conditions can be difficult to interpret because affected individuals may not produce the expected antibodies. Immunoglobulin replacement can further complicate interpretation by introducing antibodies from donors."
    },
    {
      "heading": "Treatment and clinical management",
      "text": "Immunoglobulin replacement\n\nThe principal treatment for clinically significant CVID is immunoglobulin replacement therapy, administered intravenously or subcutaneously. These preparations contain pooled donor IgG and provide passive protection against a broad range of pathogens.\n\nReplacement substantially reduces serious bacterial infections, particularly pneumonia. It does not restore normal antibody production, fully replace mucosal IgA, or reliably prevent autoimmune and inflammatory complications. Treatment is usually long term, with regimens individualized according to infection history, clinical response, and measured IgG levels.\n\nInfection control and organ complications\n\nAntibiotics are used to treat bacterial infections, and preventive antibiotic regimens are used in selected cases. Established bronchiectasis may also require airway-clearance measures and respiratory care.\n\nAutoimmune cytopenias, inflammatory lung disease, enteropathy, and other complications may require immunosuppressive treatment. Such treatment can reduce immune-mediated injury but may also increase susceptibility to infection, making management more complex than antibody replacement alone.\n\nHematopoietic stem cell transplantation is not routine treatment for CVID. It has been used in selected severe cases, particularly where life-threatening immune dysregulation or a more specifically defined immune disorder is present."
    },
    {
      "heading": "Clinical course and prognosis",
      "text": "The course of CVID varies widely. Some individuals mainly experience infections that become much less frequent with immunoglobulin replacement. Others develop progressive lung damage, gastrointestinal disease, liver disease, autoimmune complications, or malignancy.\n\nLong-term outcomes depend not only on infection control but also on the extent of organ damage and immune dysregulation. Noninfectious complications are important causes of illness and reduced survival, and can progress despite adequate replacement IgG concentrations."
    }
  ],
  "links": [
    "immune-system",
    "antibody",
    "immunodeficiency",
    "prevalence",
    "b-cell",
    "t-cell",
    "otitis-media",
    "pneumonia",
    "diarrhea",
    "autoimmune-disease",
    "anemia",
    "lymph-node",
    "spleen",
    "lymphoma",
    "stomach-cancer",
    "vaccine",
    "differential-diagnosis",
    "antibiotic",
    "immunosuppression",
    "hematopoietic-stem-cell-transplantation"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}